~ Buy the MULTRYS (cupric sulfate; manganese sulfate; selenious acid; zinc sulfate) Drug Profile, 2024 PDF Report in the Report Store ~

MULTRYS Drug Patent Profile

When do Multrys patents expire, and when can generic versions of Multrys launch?

Multrys is a drug marketed by Am Regent and is included in one NDA. There are three patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in MULTRYS is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this compound. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Multrys

Multrys was eligible for patent challenges on April 30, 2023.

Indicators of Generic Entry

Summary for MULTRYS

International Patents:	6
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for MULTRYS
What excipients (inactive ingredients) are in MULTRYS?	MULTRYS excipients list
DailyMed Link:	MULTRYS at DailyMed

See drug prices for MULTRYS

Pharmacology for MULTRYS

Drug Class	Copper Absorption Inhibitor Paramagnetic Contrast Agent
Mechanism of Action	Magnetic Resonance Contrast Activity
Physiological Effect	Decreased Copper Ion Absorption

US Patents and Regulatory Information for MULTRYS

MULTRYS is protected by three US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-003	Jun 30, 2021		RX	Yes	Yes	11,975,022
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-003	Jun 30, 2021		RX	Yes	Yes
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-003	Jun 30, 2021		RX	Yes	Yes	11,786,548		Y
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-003	Jun 30, 2021		RX	Yes	Yes	11,998,565		Y

International Patents for MULTRYS

See the table below for patents covering MULTRYS around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4175615	COMPOSITIONS D'OLIGO-ÉLÉMENTS, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION (TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE)
South Korea	20230058047	미량 원소 조성물, 그 제조 및 사용 방법
Australia	2021300384	Trace element compositions, methods of making and use
China	116096423	微量元素组合物、制备方法及应用 (Microelement composition, preparation method and application)
World Intellectual Property Organization (WIPO)	2022006426

MULTRYS Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Multiple Sclerosis Drugs: A Focus on the Industry

Introduction to Multiple Sclerosis Drugs

Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system, characterized by inflammation, demyelination, and degenerative changes. The increasing prevalence of MS, from 2.3 million cases in 2013 to 2.8 million in 2020, has driven the demand for effective treatments globally[1].

Global Market Size and Growth

The global multiple sclerosis drugs market was valued at USD 21.33 billion in 2023 and is projected to grow to USD 38.94 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 7.9% during the forecast period (2024-2032)[1].

Regional Market Dynamics

• North America: This region dominated the market with a 48.2% share in 2023, driven by significant R&D investments, new product launches, and rising demand for immunosuppressant and molecular antibody drugs[1].
• Asia Pacific: Expected to register the highest CAGR during the forecast period, driven by improved distribution networks and collaborations such as Biogen and Eisai Co., Ltd.'s co-promotion of Tecfidera, Tysabri, and Avonex in Japan[1].
• Middle East & Africa and Latin America: These regions are expected to see growth due to the rising prevalence of neurological diseases and improving healthcare spending[1].

Distribution Channels

The market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is anticipated to dominate due to favorable health reimbursement and increased government efforts to strengthen hospital pharmacies. The online pharmacy segment is also poised for significant growth, driven by the increasing number of online portals and the need for home delivery of medicines, especially post-COVID-19[1][4].

Drug Classes and Product Launches

• Immunomodulators: This segment is expected to lead the market, driven by strong sales of drugs like Mavenclad and Tecfidera. The increasing focus on developing immunomodulator drugs by market players is a key factor[4].
• New Product Launches: Recent launches and pipeline drugs, such as Adamas Pharmaceuticals Inc.'s ADS-5102, are driving market growth. These new products are the result of significant R&D investments by major market players[1].

Impact of COVID-19

The COVID-19 pandemic slowed the demand for multiple sclerosis drugs due to lower patient volumes for disease diagnosis and delays in treatment processes. However, the pandemic also accelerated the growth of the online pharmacy segment as lockdowns increased the need for home delivery of medicines[1].

Market Players

Key players such as Biogen, F. Hoffman-La Roche Ltd., Novartis AG, and Sanofi dominate the market. These companies have strong sales and are actively involved in R&D to develop innovative MS treatments. For instance, Biogen's strong sales of Tecfidera, Vumerity, and other products have significantly contributed to its market share[1][4].

Financial Performance and Revenue Streams

• Revenue Growth: The global market's revenue growth is driven by increasing government initiatives, rising prevalence of MS, and significant R&D investments. For example, the U.S. multiple sclerosis drugs market is projected to grow from USD 9.45 billion in 2023 to USD 14.10 billion by 2030, with a CAGR of 5.9%[4].
• Royalties and Milestone Payments: Companies like Ligand Pharmaceuticals have seen increases in royalty revenues and milestone payments from the approval of key programs, such as Travere Therapeutics’ FILSPARI™ and Amgen’s KYPROLIS®[2].

Research and Development Trends

The trend in drug research and development is shifting towards multi-target drugs. These drugs have shown higher potential and better market performance due to their ability to affect multiple biological pathways, which is crucial for treating complex diseases like MS[3].

Challenges and Opportunities

• Challenges: The market faces challenges such as the high cost of treatment, which can limit market growth. Additionally, the COVID-19 pandemic disrupted supply chains and reduced patient volumes for MS diagnosis and treatment[1][4].
• Opportunities: The increasing prevalence of MS and government initiatives to improve treatment accessibility present significant opportunities for market growth. The expansion of online pharmacies and the development of new, innovative drugs also offer lucrative opportunities[1][4].

Key Takeaways

• The global multiple sclerosis drugs market is expected to grow significantly, driven by R&D investments and new product launches.
• North America and Asia Pacific are key regions driving market growth.
• Immunomodulators are the leading drug class, with hospital pharmacies dominating the distribution channel.
• COVID-19 has accelerated the growth of online pharmacies.
• Major market players like Biogen and F. Hoffman-La Roche Ltd. are driving innovation and market share.

FAQs

Q: What is the projected global market size for multiple sclerosis drugs by 2032? A: The global multiple sclerosis drugs market is projected to reach USD 38.94 billion by 2032[1].

Q: Which region dominates the multiple sclerosis drugs market? A: North America dominates the market with a 48.2% share in 2023[1].

Q: What is the impact of COVID-19 on the multiple sclerosis drugs market? A: COVID-19 slowed the demand for MS drugs due to lower patient volumes and supply chain disruptions but accelerated the growth of online pharmacies[1].

Q: Which drug class is expected to lead the market? A: Immunomodulators are expected to lead the market, driven by strong sales of drugs like Mavenclad and Tecfidera[4].

Q: Who are the key players in the multiple sclerosis drugs market? A: Key players include Biogen, F. Hoffman-La Roche Ltd., Novartis AG, and Sanofi[1][4].

Cited Sources

1. Fortune Business Insights, "Multiple Sclerosis Drugs Market | Competitive Landscape [2032]"
2. Ligand Pharmaceuticals, "Ligand Reports Second Quarter 2024 Financial Results"
3. PLoS ONE, "Multi-Target Drugs: The Trend of Drug Research and Development"
4. Fortune Business Insights, "U.S. Multiple Sclerosis Drugs Market Research Report [2030]"